Equities

Shin Nippon Biomedical Laboratories Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shin Nippon Biomedical Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,429.00
  • Today's Change31.00 / 2.22%
  • Shares traded160.60k
  • 1 Year change+2.00%
  • Beta-0.0952
Data delayed at least 15 minutes, as of Jul 03 2025 03:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

  • Revenue in JPY (TTM)32.41bn
  • Net income in JPY4.92bn
  • Incorporated1973
  • Employees1.44k
  • Location
    Shin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
  • Phone+81 355655001
  • Fax+81 355656160
  • Websitehttps://www.snbl.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kidswell Bio Corp3.90bn-862.45m11.95bn42.00--9.70--3.06-22.31-22.3198.3825.870.79832.3112.7192,876,140.00-17.65-57.41-29.25-81.1330.9455.20-22.11-123.521.63-13.940.659---12.4318.93-116.31------
Chordia Therapeutics Inc0.00-2.00bn14.35bn22.00--4.42-----37.01-37.010.0047.060.00----0.00-54.42---57.62-------------642.980.00---100.00---918.09------
3-D Matrix Ltd6.93bn-2.50bn21.51bn106.00--9.70--3.10-25.15-25.1569.8720.091.120.93784.48---40.34-35.52-53.88-46.1263.8159.66-36.07-55.662.49-0.96160.5702--51.1159.47-878.94---7.64--
AnGes Inc699.31m-27.55bn22.24bn55.00--6.53--31.80-102.39-102.392.659.650.04150.27138.1912,714,800.00-163.47-42.57-191.95-49.9033.2227.35-3,939.97-7,043.231.34--0.064--320.7214.52-278.20--64.62--
Pharma Foods International Co., Ltd.61.79bn226.00m23.84bn642.0083.582.3319.400.38599.819.812,165.52352.381.781.9313.9996,250,780.000.65028.631.9422.0679.5880.640.36574.130.7778.230.564527.65-9.3742.624.0245.0128.23--
Healios KK588.00m-4.37bn45.22bn65.00--22.42--76.91-46.81-46.816.4219.270.0366--2.639,046,154.00-27.16-24.31-43.03-30.7773.30---743.03-2,817.04---1.590.7739--362.8144.46-10.78--19.31--
Shin Nippon Biomedical Laboratories Ltd32.41bn4.92bn59.66bn1.44k12.111.497.981.84118.30118.30778.58961.350.38421.245.3022,572,290.005.779.908.4014.8252.3352.6815.0123.350.6946--0.463330.4922.5517.36-10.9614.0754.7958.49
Heartseed Inc2.64bn614.54m60.87bn39.00101.488.08164.7623.0626.5826.58117.83333.720.4047--9.6067,685,900.009.42--9.89------23.28--19.27157.480.0004--153.42--44.84------
Takara Bio Inc45.04bn1.04bn96.09bn1.78k92.310.83217.832.138.658.65374.03959.190.36531.563.5725,317,030.000.88168.660.93849.7057.8863.762.4117.166.34--0.009431.403.535.44-29.59-22.8820.4616.27
GNI Group Ltd22.98bn-886.60m166.78bn867.00--4.86--7.26-17.71-17.71458.85679.050.34412.054.5826,509,560.00-3.925.12-4.986.2375.8083.27-11.4011.231.96-2.140.1530.00-9.2225.96-86.4343.2820.19--
SanBio Co Ltd0.00-4.27bn167.94bn29.00--88.62-----61.10-61.100.0026.310.00----0.00-98.97-47.32-112.89-57.01-----------4.450.4276-------9.02---46.04--
Peptidream Inc46.68bn14.82bn210.94bn621.0014.213.8212.414.52114.17114.17360.07424.190.62094.289.9075,176,500.0019.7213.4922.5515.7973.8970.0531.7526.454.7872.920.25740.0062.57--394.59------
Data as of Jul 03 2025. Currency figures normalised to Shin Nippon Biomedical Laboratories Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

11.64%Per cent of shares held by top holders
HolderShares% Held
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 05 Jun 2025946.00k2.27%
Nomura Asset Management Co., Ltd.as of 05 Jun 2025864.70k2.08%
The Vanguard Group, Inc.as of 04 Jun 2025676.43k1.63%
Asset Management One Co., Ltd.as of 05 Jun 2025652.50k1.57%
Daiwa Asset Management Co. Ltd.as of 30 May 2025405.60k0.97%
Norges Bank Investment Managementas of 30 Jun 2024373.20k0.90%
Nikko Asset Management Co., Ltd.as of 06 Jun 2025316.50k0.76%
Dimensional Fund Advisors LPas of 05 Jun 2025281.40k0.68%
Mellon Investments Corp.as of 06 Jun 2025165.10k0.40%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jun 2025163.40k0.39%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.